首页> 外文期刊>Viruses >Dendritic Cell Targeting of Bovine Viral Diarrhea Virus E2 Protein Expressed by Lactobacillus casei Effectively Induces Antigen-Specific Immune Responses via Oral Vaccination
【24h】

Dendritic Cell Targeting of Bovine Viral Diarrhea Virus E2 Protein Expressed by Lactobacillus casei Effectively Induces Antigen-Specific Immune Responses via Oral Vaccination

机译:干酪乳杆菌表达的牛病毒性腹泻病毒E2蛋白的树突状细胞靶向通过口服疫苗有效诱导抗原特异性免疫反应。

获取原文
           

摘要

Bovine viral diarrhea caused by bovine viral diarrhea virus (BVDV) is an important disease in cattle, resulting in significant economic losses to the cattle industry worldwide. In order to develop an effective vaccine against BVDV infection, we constructed a dendritic cell (DC)-targeting oral probiotic vaccine (pPG-E2-DCpep/LC W56) using Lactobacillus casei as antigen delivery carrier to express BVDV glycoprotein E2 fused with DC-targeting peptide, and the immunogenicity of orally administered probiotic vaccine was evaluated in mice model. Our results showed that after immunization with the probiotic vaccine, significantly levels of antigen-specific sera IgG and mucosal sIgA antibodies ( p 0.05) with BVDV-neutralizing activity were induced in vivo. Challenge experiment showed that pPG-E2-DCpep/LC W56 can provide effective immune protection against BVDV, and BVDV could be effectively cleared from the intestine of immunized mice post-challenge. Moreover, the pPG-E2-DCpep/LC W56 could efficiently activate DCs in the intestinal Peyer’s patches, and significantly levels of lymphoproliferative responses, Th1-associated IFN-γ, and Th2-associated IL-4 were observed in mice immunized with pPG-E2-DCpep/LC W56 ( p 0.01). Our results clearly demonstrate that the probiotic vaccine could efficiently induce anti-BVDV mucosal, humoral, and cellular immune responses via oral immunization, indicating a promising strategy for the development of oral vaccine against BVDV.
机译:牛病毒性腹泻病毒(BVDV)引起的牛病毒性腹泻是牛的重要疾病,给全世界的牛业造成了巨大的经济损失。为了开发出针对BVDV感染的有效疫苗,我们构建了以干酪乳杆菌为抗原传递载体的靶向树突状细胞(DC)的口服益生菌疫苗(pPG-E2-DCpep / LC W56),以表达与DC-融合的BVDV糖蛋白E2。靶向肽,并在小鼠模型中评估了口服益生菌疫苗的免疫原性。我们的结果表明,用益生菌疫苗免疫后,体内可显着诱导具有BVDV中和活性的抗原特异性血清IgG和粘膜sIgA抗体(p <0.05)。攻击实验表明,pPG-E2-DCpep / LC W56可以提供针对BVDV的有效免疫保护,并且可以在攻击后从免疫小鼠的肠道中有效清除BVDV。此外,pPG-E2-DCpep / LC W56可以有效激活肠道Peyer斑块中的DC,并且在用pPG-免疫的小鼠中观察到显着水平的淋巴细胞增生反应,Th1相关的IFN-γ和Th2相关的IL-4。 E2-DCpep / LC W56(p <0.01)。我们的结果清楚地表明,益生菌疫苗可以通过口服免疫有效诱导抗BVDV的粘膜,体液和细胞免疫反应,这表明开发针对BVDV的口服疫苗的有前途的策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号